AnHorn Medicines announces AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I clinical trial in the United States. The first subject was dosed this week, marking a major milestone in the development of this innovative therapy.

AnHorn Medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for AH-001 novel protein degrader program. This IND marks a significant milestone for the company, being its first regulatory achievement within just four years of its inception.

AnHorn Medicines a AI-based drug development platform focused on creating new drugs through protein degradation, has been invited to present its latest research at the NVIDIA AI Summit on June 5 in Taipei, Taiwan.

Preclinical data highlights AH-001 as potentially compelling targeted dermatology treatment options.

Company’s proprietary drug discovery platform provides unique approach to rationally design bi-functional degraders and molecular glues to have differentiated drug profiles.

After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile...